Search
Plozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigational[L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.
Reserpine
go.drugbank.com/drugs/DB00206ApprovedWithdrawnIt has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. … An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.
Mixtures: Ser-Ap-Es, Ser-AP-ES TabBictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalIt has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677] … Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection.
Categories: Antivirals used in combination for the treatment of HIV infectionsCetylpyridinium
go.drugbank.com/drugs/DB11073ApprovedInvestigationalIts salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays. … In these products, it generally mediates an antiseptic activity and protective action against dental plaque and reducing gingivitis.
Mixtures: TANTUM VERDE GENGIVITE E STOMATITE, TANTUM VERDE GENGIVITE E STOMATITECategories: Compounds used in a research, industrial, or household settingBazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalIt is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as
Abatacept
go.drugbank.com/drugs/DB01281ApprovedInvestigationalIt is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. … Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077).
Products: ORENCIA Injection 125mg/ml in Prefilled SyringeTridihexethyl
go.drugbank.com/drugs/DB00505ApprovedWithdrawnTridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. … Tridihexethyl is an antimuscarinic, anticholinergic drug. Tridihexethyl is no longer available in the US market.
Buclizine
go.drugbank.com/drugs/DB00354Approved[L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated. … It was manufactured by Stuart Pharms and initially approved by the FDA in 1957.
gamma-Hydroxybutyric acid
go.drugbank.com/drugs/DB01440ApprovedIllicitInvestigationalIt is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. … It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985).
Synonyms: oxy-n-butyric acidGaradacimab
go.drugbank.com/drugs/DB15629Approved[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … [L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema.
Categories: Drugs Used in Hereditary Angioedema